Michelle N. Bradley

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi et al. · The Lancet Diabetes & Endocrinology · 2017 · 961 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

LXR Signaling Couples Sterol Metabolism to Proliferation in the Acquired Immune Response

Steven J. Bensinger, Michelle N. Bradley, Sean B. Joseph et al. · Cell · 2008 · 719 citations · Full text

Life Sciences, Cell Biology, Immunology +13

Apoptotic Cells Promote Their Own Clearance and Immune Tolerance through Activation of the Nuclear Receptor LXR

Noelia A-González, Steven J. Bensinger, Cynthia Hong et al. · Immunity · 2009 · 668 citations · Full text

Life Sciences, Cell Biology, Immunology +14

LXR-Dependent Gene Expression Is Important for Macrophage Survival and the Innate Immune Response

Sean B. Joseph, Michelle N. Bradley, Antonio Castrillo et al. · Cell · 2004 · 572 citations · Full text

Life Sciences, Immunology, Molecular Biology +14

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Socrates E. Papapoulos, Roland Chapurlat, Cesar Libanati et al. · Journal of Bone and Mineral Research · 2011 · 344 citations · Full text

Medicine, Orthopaedic Surgery, Bone Metabolism +14